These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23130925)

  • 1. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
    Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
    J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
    Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
    Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
    Chi KN; Zoubeidi A; Gleave ME
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
    Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
    Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
    Xiu P; Dong XF; Li XP; Li J
    World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
    Schmitz G
    Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.
    Chia S; Dent S; Ellard S; Ellis PM; Vandenberg T; Gelmon K; Powers J; Walsh W; Seymour L; Eisenhauer EA
    Clin Cancer Res; 2009 Jan; 15(2):708-13. PubMed ID: 19147778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
    Rabinovich-Guilatt L; Elgart A; Erisson L; Willsie SK; Tessler S; Barnett-Griness O; Pande A; Spiegelstein O
    Br J Clin Pharmacol; 2015 Sep; 80(3):436-45. PubMed ID: 25782535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential use of custirsen to treat prostate cancer.
    Higano CS
    Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: G-3139.
    Banerjee D
    Curr Opin Mol Ther; 1999 Jun; 1(3):404-8. PubMed ID: 11713806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the apoptosis pathway in prostate cancer.
    Zielinski RR; Eigl BJ; Chi KN
    Cancer J; 2013; 19(1):79-89. PubMed ID: 23337761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.